Codexis Inc (CDXS) Stock Price, Quote & News

Company Profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 421 8100

Website: www.codexis.com

Address:

200 Penobscot Drive, Redwood City, United States

Jdnguyen24 Aug. 24 at 5:03 AM

$CDXS She added that the next challenge would be to find a way to extend the approach to other types of cancer that may be harder to treat than melanoma, a deadly skin cancer with an estimated 112,000 new cases per year in the United States. The study is the most advanced of a number of trials testing the approach against a variety of cancers, including lung, bladder, kidney and pancreatic cancer. While small trials have shown the promise of the approach, the Moderna and Merck trial was seen as a bellwether in demonstrating the technology — and a first step toward transforming cancer care with treatments that are individualized to a person’s tumor and that may ultimately be able to stay ahead of it as it changes. “Folks like myself in the community have been waiting for this,” Dr. Sayour said, adding, “We believed in this, we expected this, but I think there’s tremendous capacity for enhancing these approaches.”

0 · Reply

Jdnguyen24 Aug. 24 at 5:02 AM

$CDXS Scientists create intismeran by sequencing the patient’s tumor and selecting what are called “neoantigens,” which teach the immune system how to attack the cancer. They use the fast, flexible mRNA technology to create a vaccine with neoantigens selected for each patient — a process that takes about six weeks. “It is certainly gratifying to see these exciting results — to come full circle, from our early proof-of-concept results to now,” Dr. Catherine Wu, a professor of medicine at Harvard Medical School and the Dana-Farber Cancer Institute and a leader in the field, wrote in an email. In 2017, Dr. Wu’s lab demonstrated the promise of customized vaccines that train a fighting force of immune cells to target the specific neoantigens on an individual patient’s tumor. “That was the starting point of the field. These were small studies, less than 20 patients,” Dr. Wu said.

0 · Reply

Jdnguyen24 Aug. 24 at 5:02 AM

$CDXS The mRNA technology that was instrumental in the rapid vaccine development in the Covid-19 pandemic added a new element of speed and flexibility to the quest for therapeutic cancer vaccines. Scientists can use the mRNA platform to create bespoke, individualized vaccines matched to the genetics of patients’ tumors. The companies announced only the broad outline of the results of the large, closely watched trial and plan to present the details at an international medical meeting and to regulators. In the late-stage trial of 1,137 people with high-risk melanoma who underwent surgery to have their cancer removed, those who received the personalized cancer vaccine, called intismeran, along with an immunotherapy drug called Keytruda were less likely to see their cancer recur or spread compared with those who received just Keytruda.

0 · Reply

Jdnguyen24 Aug. 24 at 5:01 AM

$CDXS A New mRNA Vaccine Could Prevent Skin Cancer From Returning Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients. NYT: By Carolyn Y. Johnson Aug. 19, 2026. An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, the pharmaceutical companies Moderna and Merck announced Wednesday. For decades, cancer vaccines have been one of the most tantalizing ideas in cancer treatment — offering the hope of harnessing a person’s own immune system to attack tumors. “It’s a big deal,” said Dr. Elias Sayour, a pediatric oncologist at the University of Florida, who was not involved in the trial. The results, he said, “could help usher a whole new wave of new therapeutic treatments for cancer.”

1 · Reply

JulesRocketManVern Aug. 20 at 10:54 AM

$CDXS pre market building.....

1 · Reply

Fingerlickengood Aug. 20 at 9:20 AM

$CDXS This all I know. “CodeEvolver has been used to engineer next-generation enzymes like the Codex® HiCap RNA Polymerase. Enhanced Capping Efficiency: Natural RNA polymerases require high concentrations of capping reagents. CodeEvolver-optimized polymerases are engineered to selectively incorporate the 5' cap at initiation, dramatically increasing capping efficiency while using fewer raw materials.” https://www.aldevron.com/custom-manufacturing/rna/mrna-production-codex-hicap https://ir.codexis.com/news-events/press-releases/detail/377/codexis-and-aldevron-enter-exclusive-licensing-agreement-for-codex-hicap-rna-polymerase https://ir.codexis.com/news-events/press-releases/detail/94/codexis-completes-transfer-of-codeevolver-technology-to-merck

0 · Reply

galaxySky Aug. 20 at 12:16 AM

$CDXS @Fingerlickengood no idea if there is any connection with Merck and today’s Moderna news that may in some way relate to codexis? Probably a long shot given how large those companies are but thought I’d ask you since you’ve made many cross checks before!

4 · Reply

Camille65 Aug. 19 at 4:41 PM

$CDXS this stock as hopless as its managment team, going sideways until they pull a rabbit from the ECO hat. Over promise, under (no) deliver and crash the stock!

1 · Reply

Fingerlickengood Aug. 19 at 4:38 PM

$CDXS Nice! https://www.nytimes.com/2026/08/19/science/moderna-merck-mrna-vaccine-melanoma.html

0 · Reply

Valueforall Aug. 18 at 3:05 PM

$CDXS I wonder if management and this new ceo is capable of executing! Here is the exact operational playbook management must execute: 1. Hayward Validation: Translate the $8.25M permit into a fully operational GMP cleanroom, cleanly scaling from 100g pilots to kg-scale batches for partner Phase 1/2 trials. 2. Lock In CDMO Partners: Secure formal tech-transfer and licensing deals with major CDMOs (e.g., Bachem) to handle late-stage/commercial volume off-take. 3. Big Pharma Conversion: Convert early evaluation trials into exclusive multi-year platform licenses, proving ECO delivers superior purity, stereoisomer control, and lower COGS versus traditional chemical synthesis. 4. Monetize High-Margin Supply: Structure deals to capture recurring, high-margin enzyme supply revenue and per-gram royalties as client siRNA pipelines reach commercial scale. Nail this sequence, and ECO Synthesis becomes the universal standard for enzymatic RNA manufacturing

1 · Reply

Market Cap	182.88M
Revenue (ttm)	70.39M
Net Income (ttm)	-43.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-62.47%
Debt to Equity Ratio	1.03

Volume	1,257,900
Avg Vol	1,215,370
Day's Range	N/A - N/A
Shares Out	109.51M
Stochastic %K	89%
Beta	2.54
Analysts	Strong Sell
Price Target	$6.33